M. Tan

发表

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.

I. Flinn, A. Wiestner, S. O'brien, 2022, Journal of Clinical Oncology.

POS0006 NX-5948, A SELECTIVE DEGRADER OF BTK, SIGNIFICANTLY REDUCES INFLAMMATION IN A MODEL OF AUTOIMMUNE DISEASE

Mark Noviski, C. Guiducci, R. Rountree, 2021 .

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

I. Flinn, O. Abdel-Wahab, A. Wiestner, 2022, Blood.

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

G. Hansen, Mark Noviski, C. Guiducci, 2021, Blood.

Abstract 1126: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing

Jun Ma, C. Guiducci, R. Rountree, 2022, Cancer Research.

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

A. Zelenetz, O. Abdel-Wahab, A. Linley, 2022, Blood.

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Dahlia R. Weiss, A. Sands, C. Guiducci, 2020 .

Abstract 3423: NX-2127: A first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies

Brandon J. Bravo, Stephanie L. Yung, J. Mcintosh, 2023, Cancer Research.